Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32220| Title: | Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer. | Austin Authors: | Verhoek, Andre;Cheema, Parneet;Melosky, Barbara;Samson, Benoit;Shepherd, Frances A;de Marinis, Filippo;John, Thomas ;Wu, Yi-Long;Heeg, Bart;Van Dalfsen, Nadia;Bracke, Benjamin;Miranda, Miguel;Shaw, Simon;Moldaver, Daniel | Affiliation: | William Osler Health System, University of Toronto, Toronto, ON, Canada. Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada. Charles LeMoyne Hospital Cancer Center, Greenfield Park, QC, Canada. Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto, ON, Canada. Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy. Medical Oncology Department of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Cytel, Weena 316-318, 3012 NJ, Rotterdam, The Netherlands. Global Health Economics and Payer Evidence, AstraZeneca, Cambridge, UK. Global Medical Development, AstraZeneca, Cambridge, UK. Global Medical Affairs, AstraZeneca, Cambridge, UK. Health Economics and Payer Evidence, AstraZeneca, Mississauga, ON, Canada. |
Issue Date: | 22-Feb-2023 | Date: | 2023 | Publication information: | PharmacoEconomics - Open 2023 | Abstract: | For many patients with resected epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), current standard of care (SoC) is adjuvant chemotherapy; however, disease recurrence remains high. Based on positive results from ADAURA (NCT02511106), adjuvant osimertinib was approved for treatment of resected stage IB‒IIIA EGFRm NSCLC. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32220 | DOI: | 10.1007/s41669-023-00396-0 | ORCID: | 0000-0003-3958-0033 |
Journal: | PharmacoEconomics - Open | PubMed URL: | 36811822 | ISSN: | 2509-4254 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.